Dr. Blackledge is an experienced analytical chemist with a background of over twenty years in pharmaceutical drug development. His specialty is biological mass spectroscopy, and his research interests include the development and implementation of mass spectroscopic and chromatographic techniques for the development of nanoparticulate drugs. This area of research spans both large and small molecules, as the macromolecular structures involved are composed of a variety of different species. Prior to the founding of Capella Imaging, Jim worked in the Research & Development functions of Bristol-Myers Squibb, Parke-Davis, Kereos, Inc, and Mallinckrodt Pharmaceuticals. Presently he also serves as Director of Analytical and Bioanalytical Chemistry at Galera Therapeutics.
Dr. Blackledge is an experienced analytical chemist with a background of over twenty years in pharmaceutical drug development. His specialty is biological mass spectroscopy, and his research interests include the development and implementation of mass spectroscopic and chromatographic techniques for the development of nanoparticulate drugs. This area of research spans both large and small molecules, as the macromolecular structures involved are composed of a variety of different species. Prior to the founding of Capella Imaging, Jim worked in the Research & Development functions of Bristol-Myers Squibb, Parke-Davis, Kereos, Inc, and Mallinckrodt Pharmaceuticals. Presently he also serves as Director of Analytical and Bioanalytical Chemistry at Galera Therapeutics.
17011 Beach Blvd, Suite 500 Huntington Beach, CA 92647
714-847-3540© 2025 Life Science Intelligence, Inc., All Rights Reserved. | Privacy Policy